About Kevin Bitterman
Form D filings for Remix Therapeutics in 2024 list Kevin Bitterman as director.
Kevin Bitterman first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Kevin Bitterman in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Kevin Bitterman works with at each company, as listed on that company's latest Form D.
Remix Therapeutics, Inc. · Form D, Jan 4, 2024
PS
Peter Smith
President & CEO, director
RG
Robert Gagnon
Executive officer
MP
Matthew Patterson
Director
JG
Jeff Goater
Director
MR
Michael Rome
Director
SB
Scott Biller
Director
HW
Heather Wasserman
Executive officer